Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab. Davies GA, Prica A, Ante Z, Liu N, et al. Cancer 2026;132:e70327.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Davies GA, Prica A, Ante Z, Liu N, et al. Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab. Cancer 2026;132:e70327.
PMID: 41773899